Investors - group.medisonal.co.uk

Note to Investors

We value our investors immensely and are fortunate to have strategic investors who are committed in sharing our journey. We have true partnerships where we regularly meet to discuss our strategic direction, business plan and work together to overcome any hurdles that may come our way. We are always interested in working with other investors who can help us grow and who can lend their expertise to enable us to achieve our ambitious goals by working efficiently together.

Medisonal is funding our future plans!

In today’s dynamic healthcare landscape, innovation and technology are the cornerstones of global success. To harness these transformative forces and propel our healthcare business to new heights, we invite a diverse pool of investors to join us in this exciting journey.

Founder Message

Several years ago, I started to notice Cannabis-Based Products for Medicinal Use (CBPM) in the news. In one particular week towards the end of 2017, I heard it mentioned three times in as many conversations. It was then I realised I needed to look more closely into it.

At the time, I was recovering from a shoulder operation following a skiing accident and had been prescribed an opiate-based painkiller. It numbed the pain alright, but after experiencing some very unpleasant side effects, including drowsiness, I decided to stop taking them.

What I’d heard prompted me to try some CBPM instead, and this more natural approach gave me some relief, yet without the associated symptoms mentioned above. By comparison, the CBPM didn’t give me any side effects and I felt some relief in the constant throbbing of my shoulder.

This first-hand experience increased my interest, and I started having discussions with a new manufacturer who was about to embark on building a super high-tech, EU-GMP facility (now up and running). As I monitored developments in Germany and other EU countries, it became obvious that it was only a matter of time before the UK followed, so I decided to found Medisonal to help patients access medical cannabis.

In early 2018, several high-profile UK cases gave CBPM the exposure it needed. On 1 November 2018, some incredible lobbying of the UK government by parents of children affected by conditions known to be treatable with CBPM led, at last, to the reclassification of cannabis to schedule 2 of the Misuse of Drugs act of 1971. Despite this, over two years later, access to cannabis-based medicine in the UK remains a challenge.

Since 2017, I have been researching the UK market and seeking out the best management team to accompany me on my Medisonal journey. Today, I’m proud to have in place a core management and advisory team who are each ‘best-in-class’, experienced in their own field and bringing a unique skill set to the table.

Meanwhile, as I foresaw, developments are gaining momentum. These developments will see medical Cannabis shed its taboos and become as accepted as other plant-based remedies with incredible healing properties.

Investment Highlights

Proven track record of innovation: Our team has developed our proof of concept into a current healthcare solution that will significantly improve patient care. As soon as we receive our CQC registration, we are ready to go live. We have doctors and patients ready to go once we go live.
Strong market position: We are well-positioned in a rapidly growing market with significant unmet needs.
Experienced leadership team: Our leadership team brings deep expertise in healthcare, technology, and business development and well as banking and finance.
Commitment to social responsibility: We are dedicated to using our innovations to improve the lives of people around the world.

Your investment will fuel our ground-breaking initiatives, enabling us to

Pioneer cutting-edge healthcare solutions: We are committed to developing innovative healthcare technologies that address the most pressing medical challenges. Your investment will empower us to accelerate the development of these solutions, improving patient outcomes and transforming the healthcare industry.
Expand our global reach: With your support, we will expand our presence into new markets, bringing our innovative healthcare solutions to underserved communities worldwide. Your partnership will enable us to make a profound impact on global health.
Foster a collaborative ecosystem: We believe in the power of collaboration to drive innovation. Your investment will foster a vibrant ecosystem of partners, including researchers, clinicians, and industry experts, accelerating our progress towards groundbreaking healthcare solutions.

We seek investors who share our vision of a future where healthcare is accessible, affordable, and life-changing for all. Together, we can make a lasting impact on the world.

Our Team

Our Experienced Management Team

Lloyd Michaels

Founder

Lloyd founded Medisonal to be part of one of the biggest game changers of our generation. He intends to make a positive impact on both the industry and patients’ lives by making CBPM more accessible. He has worked in Investment banking since 1996 for some of the world’s largest banks. Having lived abroad for 7 years, most notably working in Hong Kong for 4 of those, he has established a reliable global network of contacts from multiple disciplines and industries which will benefit the development of the business.

Hana Salussolia

CEO

Hana worked in financial services for over 15 years and held senior positions in leading global investment banks. Her last banking role was Managing Director at Goldman Sachs. Hana has worked in Biotech for the past 5 years. She is also Founder and Treasurer of charity Microtia, where she played an integral part in helping to change NICE (NHS) guidelines for treatment of those with Microtia. Hana has been philanthropist for over 20 years, helping to secure funding for variety of projects and institutions including GOSH, UCL & The Royal Free.

Dr. Anthony Ordman

Lead clinician

Anthony is a senior consultant in pain medicine. He graduated from the University of London in 1978, and has been a specialist in pain medicine for 25 years, founding a respected NHS teaching hospital pain clinic and teaching young pain specialists and doctors. He was appointed to a special Fellowship of the Royal College of Physicians, and was President of the Pain Medicine Section at the Royal Society of Medicine.

Always an innovator, Anthony began to prescribe cannabis medicines for pain, feeling they were often better and safer than many conventional medicines. He helped set up a leading UK cannabis medicine clinic, and lectures on the subject.

Anthony is helping to develop the role of cannabis medicines in all areas of health care, and to develop new and innovative ways of delivering these medicines.

Katrina Boulton

Lead Nurse

Katrina (Kat) started in healthcare over a decade ago and has been a Registered Adult Nurse for the past 5 years. Following experience in A&E Trauma Nursing she returned to palliative care in the Hospice setting and then specialised in Chronic Pain as a Neuromodulation Pain Sister, continuing her education through PgC (Epilepsy Nursing), MSc Neuromodulation Module and now Advanced Clinical Practice (MSc).

She has a daughter diagnosed with a genetic disorder causing refractory epilepsy, finding improvement with prescribed cannabis medicine. This passion for medical cannabis led her to become a Cannabis Nurse with over one years previous experience in this specialist area.

With an extensive variety of patient nursing experience, she has the personal and professional knowledge to bring to the role of Lead Nurse in the Medical Cannabis clinical setting. Her main aim will be to to holistically support patients’ accessing medical cannabis. This will be achieved by offering support to the clinical team in delivery of this care so that patients can look forward to a better quality of life.

Carl Woolf

Pharmaceutical Director

After qualifying as a Pharmacist in 1991, Carl owned and managed numerous retail pharmacies. He branched out in 2014, opening a private out-patient hospital where he still works today. Carl still operates a pharmacy within the hospital and is a partner in Cloud RX.

Laurence Busch Hansen

Scientific Advisor

Laurence comes from a scientific background having graduated in Pharmacology before moving to UCL to complete a Masters degree in Drug Discovery and Pharma Management. Since then, Laurence has worked at London’s Global cannabis consultancy, Hanway Associates, where he provided services such as competitor analysis, M&A strategy and licencing advice to a large variety of cannabis companies across Europe.

Thomas Levene

Research & New Business Development

Thomas joined Medisonal with prior experience within the cannabis industry. Having created several start-ups in a range of areas, he has been tasked with identifying new business opportunities. He is also responsible for liaising with our research department and scientific partners in order to align our commercial and scientific interests. He has gained a BSc (Hons) in film production technology from Nottingham Trent University; He will be using his skills to add a different dimension to the creative side of our business.

Andrew Case

Legal Counsel

Andrew has enjoyed a 30-year career in law and compliance with an emphasis on investment and asset management and securities law matters. Mr. Case was associated with Rogers & Wells in New York and Baker & McKenzie in Hong Kong, specializing in IPOs and M&A. He then joined Merrill Lynch and later Morgan Stanley where he managed those banks’ cross-border financing and M&A work in Hong Kong and London. He has acted as the compliance officer for a number of private equity and financial firms, including Forum Partners, HBS London and the Duet Group. Mr. Case received a B.A. (magna cum laude) from Yale University, and he is Juris Doctor from Columbia University. He is also a member of the New York and Connecticut bars.

Our Advisors

Donald Featherstone

Non-Executive Director

Donald Featherstone joins the Medisonal Board of Directors in the role as an NED. Donald is the Senior Managing Director at Ankura and is based in London. Donald has more than 30 years of professional experience in finance and corporate governance. He has advised a variety of clients on capital raising and refinancing strategies across a wide range of industries and geographies. Prior to joining Ankura, Donald was a Managing Director and Partner at the Boston Consulting Group. Donald has served on the board of a number of companies including O3B Satellite Networks, SeaTrucks International, and Viking SeaTech.

Nick Davis

Legal Advisor

Nick Davis is Chief Executive of Memery Crystal and a senior corporate partner. Nick has positioned himself at the forefront of the medical cannabis market in the UK and was one of the key actors in lobbying the FCA to agree the listing of cannabis related business on London’s primary markets, the Official List.